Business
AstraZeneca invests $15bn in China through 2030
AstraZeneca announced a significant $15 billion investment in China through 2030, aimed at expanding its capabilities in discovering, developing, and manufacturing innovative medicines, particularly in areas like cell therapy and radioconjugates. This strategic investment will leverage China's scientific and manufacturing strengths to deliver next-generation treatments to patients both domestically and globally, supporting AstraZeneca's 2030 ambitions and enhancing its end-to-end cell therapy capabilities in China. The plan includes developing existing manufacturing facilities and establishing new ones, growing its workforce in China to over 20,000, and fostering collaborations with leading Chinese biotechs and UK research institutions. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n29 January 2026\n \nAstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines\n \nLandmark investment will expand AstraZeneca's capabilities to discover, develop, and manufacture transformative new treatments in China\n \nInvestment will support delivery of AstraZeneca's 2030 ambition\n \nAstraZeneca today announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country's scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.\n \nKeir Starmer, UK Prime Minister, said: \"Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements. AstraZeneca's expansion and leadership in China will help the British manufacturer continue to grow - supporting thousands of UK jobs. The multi-billion pound investment announced today from AstraZeneca, alongside partnerships from some of our country's leading universities, furthers research and development in the UK which is helping to power our world class life sciences sector.\"\n \nPascal Soriot, Chief Executive Officer, AstraZeneca, said: \"Today's landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China's high-quality development and, most importantly, bring next-generation modalities to patients.\"\n \nRecognising China's advanced science in new modalities, this investment will significantly enhance the Company's cell therapy and radioconjugates capabilities that are driving its broad and varied pipeline to help patients with cancer, haematological conditions and autoimmune diseases, among others. These investments span the value chain, from drug discovery and clinical development to manufacturing, and bring Chinese innovation to the world through our partnerships with leading biotechs including AbelZeta, CSPC, ...